Using blood tests to monitor cancer in patients with advanced tumors
Implementation of Liquid Biopsies During Routine Clinical Care in Patients With Advanced Malignancies (LIQPLAT)
This study is testing if using blood tests to check for cancer-related DNA can help doctors better manage and treat patients with advanced tumors.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 150 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Basel, Switzerland Academic / other |
| Locations | 1 site (Basel) |
| Trial ID | NCT06367751 on ClinicalTrials.gov |
What this trial studies
This study aims to evaluate the feasibility of implementing liquid biopsies, specifically measuring circulating tumor DNA (ctDNA), during routine clinical care for patients with advanced solid tumors at the University Hospital Basel. Researchers will compare clinical outcomes and patient-reported outcomes between those receiving ctDNA measurements and a control group from an external registry. Blood samples will be collected as part of standard care, and ctDNA analysis will help identify mutations, assess disease burden, and tailor treatment strategies. The study seeks to integrate ctDNA measurements into routine practice to enhance patient management and outcomes.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with advanced solid tumors who have not received prior treatment for metastatic disease.
Not a fit: Patients with primary brain tumors will not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more personalized cancer treatment and improved patient outcomes.
How similar studies have performed: Other studies have shown promise in using ctDNA for monitoring cancer, but this specific implementation in routine care is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with a proven solid malignant disease, i.e. with solid malignant tumors where no primary surgical resection is planned OR solid malignant tumors that are locally advanced and inoperable OR solid tumors that are metastatic * No prior treatment for advanced/metastatic disease * Indication for medical anti-cancer treatment (including combined chemoradiotherapy) as judged by the treating physician * Patient age 18 years and older * General research consent of the University Hospital Basel Exclusion Criteria: ● Patients with primary brain tumors
Where this trial is running
Basel
- Department of Medical Oncology, University Hospital Basel — Basel, Switzerland (Recruiting)
Study contacts
- Principal investigator: Benjamin Kasenda, PD. Dr. med et Dr. phil. — Usb
- Study coordinator: Benjamin Kasenda, PD. Dr. med et Dr. phil.
- Email: Benjamin.Kasenda@usb.ch
- Phone: 0041 61 265 50 75
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.